Dare Bioscience (DARE) vs Pasithea Therapeutics (KTTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Dare Bioscience (DARE) over the past year, losing 45.4% versus a loss of 66.3%. Over five years, DARE leads with a -95.9% price change compared with -99.3% for KTTA. Dare Bioscience is the larger company by market cap ($15.2 million vs $14.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DARE | KTTA |
|---|---|---|
| Share price | $0.7722 | $0.4409 |
| Market cap | $15.19M | $14.73M |
| 1-day change | -2.25% | -0.56% |
| YTD return | -59.99% | -65.63% |
| 1-year return | -66.28% | -45.39% |
| 5-year return | -95.90% | -99.26% |
| EPS (TTM) | $-0.71 | $-1.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.78 | $2.06 |
| 52-week low | $0.69 | $0.281 |
| Distance from 52-week high | -79.57% | -78.60% |
| Analyst consensus | none | none |
| Avg. price target upside | +978.74% | +580.43% |
| Average volume | 524.37K | 225.69K |
| Shares outstanding | 19.67M | 33.41M |
| Employees | 21 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed DARE by 20.9 percentage points over the past year.
About Dare Bioscience
DARE stock →Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.
Healthcare · Biotechnology · 21 employees
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Healthcare · Biotechnology · 5 employees
DARE vs KTTA FAQ
Which is bigger, Dare Bioscience or Pasithea Therapeutics?
Dare Bioscience (DARE) is larger, with a market capitalization of $15.19M compared with $14.73M for Pasithea Therapeutics (KTTA).
Which stock has performed better over the past year, DARE or KTTA?
KTTA returned -45.39% over the past 12 months, compared with -66.28% for DARE (price return, excluding dividends). Past performance does not predict future results.
Are Dare Bioscience and Pasithea Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.